← Eichor
Study identifier: NCT06787989 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases

Condition: Refractory Immune Cytopenia  ·  Sponsor: iCell Gene Therapeutics

PhasePhase 1
Planned participants20
Who can joinAll sexes, 18 Years to 60 Years
Healthy volunteersNo

About this study

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR T cells in patients with refractory ITP associated with autoimmune disease.

This description comes directly from the study's public registry record.

Talk to the study team

Qibing Xie, MD  ·  0118618980601299  ·  xieqibing1971@163.com

Min Yang, MD  ·  13618028207  ·  yangmin7911@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

West China HospitalChengdu, Sichuan, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06787989